https://www.selleckchem.com/pr....oducts/msu-42011.htm
uld rigorously measure EIMs in parallel with objective measures of luminal disease activity to provide more robust data on the relative efficacy of new drugs, especially as increasing numbers of gut-selective compounds enter clinical development.Gene rearrangements involving the neurotrophic receptor kinase genes NTRK1, NTRK2, and NTRK3 (referred to as TRK, encoding TRKA, TRKB, and TRKC, respectively) result in highly oncogenic fusions. TRK fusions are rare, with a prevalence of less then 1% in solid tumors. Detection of TRK fusions c
پسندیدن
اظهار نظر
اشتراک گذاری
